BTAI Earnings BioXcel Therapeutics, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–23 of 23
| Q2 2026 | 2026-06-30 | -1.02 | 2026-08-13 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.54 | 2026-05-15 | 10-Q |
| FY 2025 | 2025-12-31 | -5.73 | 2026-03-27 | 10-K |
| Q3 2025 | 2025-09-30 | -6.38 | 2025-11-12 | 10-Q |
| Q2 2026 | 2025-06-30 | -4.17 | 2026-08-13 | 10-Q |
| Q1 2026 | 2025-03-31 | -1.50 | 2026-05-15 | 10-Q |
| FY 2025 | 2024-12-31 | -23.51 | 2026-03-27 | 10-K |
| Q3 2025 | 2024-09-30 | -20.60 | 2025-11-12 | 10-Q |
| Q2 2025 | 2024-06-30 | -15.78 | 2025-08-12 | 10-Q |
| Q1 2025 | 2024-03-31 | -13.89 | 2025-05-12 | 10-Q |
| FY 2024 | 2023-12-31 | -98.33 | 2025-03-28 | 10-K |
| Q3 2024 | 2023-09-30 | -5.40 | 2024-11-14 | 10-Q |
| Q2 2024 | 2023-06-30 | -3.68 | 2024-08-06 | 10-Q |
| Q1 2024 | 2023-03-31 | -1.84 | 2024-05-09 | 10-Q |
| FY 2023 | 2022-12-31 | -5.92 | 2024-03-22 | 10-K |
| Q3 2023 | 2022-09-30 | -3.96 | 2023-11-14 | 10-Q |
| Q2 2023 | 2022-06-30 | -2.47 | 2023-08-14 | 10-Q |
| Q1 2023 | 2022-03-31 | -1.12 | 2023-05-09 | 10-Q |
| FY 2022 | 2021-12-31 | -4.05 | 2023-03-16 | 10-K |
| Q3 2022 | 2021-09-30 | -3.13 | 2022-11-14 | 10-Q |
| Q2 2022 | 2021-06-30 | -2.18 | 2022-08-11 | 10-Q |
| Q1 2022 | 2021-03-31 | -1.08 | 2022-05-09 | 10-Q |
| FY 2021 | 2020-12-31 | -3.79 | 2022-03-11 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.